Axsome Therapeutics, Inc. (NASDAQ:AXSM) Short Interest Update

by · The Cerbat Gem

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 2,835,683 shares, a decrease of 16.7% from the November 30th total of 3,404,883 shares. Currently, 7.2% of the company’s stock are short sold. Based on an average daily volume of 488,863 shares, the short-interest ratio is presently 5.8 days. Based on an average daily volume of 488,863 shares, the short-interest ratio is presently 5.8 days. Currently, 7.2% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Cowen reissued a “buy” rating on shares of Axsome Therapeutics in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Wednesday, October 8th. Oppenheimer reissued an “outperform” rating and issued a $220.00 price objective on shares of Axsome Therapeutics in a research report on Wednesday. Needham & Company LLC increased their target price on shares of Axsome Therapeutics from $154.00 to $169.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Guggenheim lifted their price target on shares of Axsome Therapeutics from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $183.94.

Check Out Our Latest Stock Report on Axsome Therapeutics

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 91,705 shares of Axsome Therapeutics stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $132.34, for a total value of $12,136,239.70. Following the sale, the chief executive officer owned 7,229 shares of the company’s stock, valued at $956,685.86. This trade represents a 92.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last three months, insiders sold 289,296 shares of company stock worth $38,882,311. 22.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Axsome Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AXSM. Versant Capital Management Inc boosted its stake in shares of Axsome Therapeutics by 20,300.0% during the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock worth $25,000 after acquiring an additional 203 shares during the period. First Horizon Corp bought a new stake in Axsome Therapeutics in the 3rd quarter valued at $34,000. Optiver Holding B.V. lifted its holdings in Axsome Therapeutics by 82.3% during the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after purchasing an additional 130 shares during the last quarter. AlphaQuest LLC bought a new position in Axsome Therapeutics during the first quarter worth $38,000. Finally, Essex Investment Management Co. LLC acquired a new position in shares of Axsome Therapeutics in the third quarter valued at $38,000. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Price Performance

Shares of AXSM opened at $182.64 on Friday. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66. The company’s fifty day simple moving average is $146.30 and its 200 day simple moving average is $124.92. Axsome Therapeutics has a 1-year low of $79.19 and a 1-year high of $184.40. The company has a market cap of $9.21 billion, a price-to-earnings ratio of -39.11 and a beta of 0.44.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). The firm had revenue of $170.99 million during the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. Axsome Therapeutics’s revenue was up 63.2% on a year-over-year basis. On average, research analysts forecast that Axsome Therapeutics will post -2.79 earnings per share for the current fiscal year.

About Axsome Therapeutics

(Get Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.

Featured Stories